bluebird bio, Inc. Form 4 June 11, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average burden hours per

OMB APPROVAL

3235-0287

0.5

OMB

Number:

response...

Form 5 obligations may continue. *See* Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Walsh Jeffrey T.	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) (Middle)	bluebird bio, Inc. [BLUE] 3. Date of Earliest Transaction			
	(Month/Day/Year)	Director 10% Owner		
C/O BLUEBIRD BIO, INC., 150 SECOND STREET	06/10/2015	_X_ Officer (give title Other (specify below)		
(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
CAMBRIDGE, MA 02141	Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting		
		Person		

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit on Disposed (Instr. 3, 4)	of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	06/10/2015		M	10,455	A	\$ 2.09	10,455	D		
Common Stock	06/10/2015		M	545	A	\$ 2.09	11,000	D		
Common Stock	06/10/2015		S <u>(1)</u>	2,200	D	\$ 178.6126 (2)	8,800	D		
Common Stock	06/10/2015		S <u>(1)</u>	3,610	D	\$ 179.2419 (3)	5,190	D		
	06/10/2015		S <u>(1)</u>	4,332	D		858	D		

Edgar Filing: bluebird bio, Inc. - Form 4

Common \$ 180.316 Stock Common $S^{(1)}$ 06/10/2015 \$ 181.33 0 858 Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control

D

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of ctionDerivative Securities 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Derivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 2.09	06/10/2015		M		10,455	<u>(5)</u>	07/13/2021	Common Stock	10,455
Stock Otpion (right to buy)	\$ 2.09	06/10/2015		M		545	<u>(5)</u>	07/13/2021	Common Stock	545

Dolotionchine

Reporting Owners

Reporting Owner Name / Address	Keiationsinps						
	Director	10% Owner	Officer	Other			
Walsh Jeffrey T. C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE, MA 02141			Chief Operating Officer				

Date

Signatures

**Signature of Reporting Person

/s/ Jason F. Cole, 06/11/2015 Attorney-in-Fact

2 Reporting Owners

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 26, 2014.
- The range of prices for the transaction reported on this line was \$178.02 to \$178.83. The average weighted price was \$178.6126. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was \$179.00 to \$179.78. The average weighted price was \$179.2419. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was \$180.00 to \$180.90. The average weighted price was \$180.3160. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number
- of shares sold at each separate price.
- (5) This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.